MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 590-597

  Togashi, Yosuke ^a   Mizuuchi, Hiroshi ^a   Tomida, Shuta ^a   Terashima, Masato ^a   Hayashi, Hidetoshi ^a   Nishio, Kazuto ^a   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CRISPR Cas9; Crizotinib; Lung adenocarcinoma; MET exon 14 deletion

Indexed keywords

CRIZOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SCATTER FACTOR RECEPTOR; GUIDE RNA; PROTEIN KINASE INHIBITOR; RNA SPLICING;

ARTICLE; CELL GROWTH; COLONY FORMATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; EXON; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INHIBITORY CONCENTRATION; LUNG ADENOCARCINOMA; NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; BIOLOGY; CELL PROLIFERATION; CHEMISTRY; DNA SEQUENCE; DRUG RESISTANCE; GENE TARGETING; GENETIC DATABASE; GENETICS; LUNG NEOPLASMS; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; RNA SPLICING; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; CRISPR-CAS SYSTEMS; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; EXONS; GENE TARGETING; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RNA SPLICE SITES; RNA, GUIDE; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION;

EID: 84949235040     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.10.020     Document Type: Article

References (36)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29. PubMed PMID: 24399786. 10.3322/caac.21208.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500. Epub 2004/05/01. PubMed PMID: 15118125. 10.1126/science.1099314.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350(21):2129-2139. Epub 2004/05/01. PubMed PMID: 15118073. 10.1056/NEJMoa040938.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(36):13306-13311. PubMed PMID: 15329413; PubMed Central PMCID: PMCPMC516528. 10.1073/pnas.0405220101.
5. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361(10):947-957. Epub 2009/08/21. PubMed PMID: 19692680. 10.1056/NEJMoa0810699.
6. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11(2):121-128. Epub 2009/12/22. PubMed PMID: 20022809. 10.1016/s1470-2045(09)70364-x.
7. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010, 362(25):2380-2388. Epub 2010/06/25. PubMed PMID: 20573926. 10.1056/NEJMoa0909530.
8. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011, 12(2):175-180. PubMed PMID: 21277552. 10.1016/S1470-2045(10)70087-5.
9. Cooper C.S., Park M., Blair D.G., Tainsky M.A., Huebner K., Croce C.M., et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311(5981):29-33. PubMed PMID: 6590967.
10. Naldini L., Vigna E., Narsimhan R.P., Gaudino G., Zarnegar R., Michalopoulos G.K., et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991, 6(4):501-504. PubMed PMID: 1827664.
11. Trusolino L., Bertotti A., Comoglio P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010, 11(12):834-848. PubMed PMID: 21102609. 10.1038/nrm3012.
12. Califano R., Abidin A., Tariq N.U., Economopoulou P., Metro G., Mountzios G. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treat. Rev. 2015, 41(5):401-411. PubMed PMID: 25842168. 10.1016/j.ctrv.2015.03.009.
13. Li A., Gao H.F., Wu Y.L. Targeting the MET pathway for potential treatment of NSCLC. Expert Opin. Ther. Targets 2015, 19(5):663-674. PubMed PMID: 25532429. 10.1517/14728222.2014.995093.
14. Hack S.P., Bruey J.M., Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014, 5(10):2866-2880. PubMed PMID: 24930887; PubMed Central PMCID: PMCPMC4102777.
15. Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012, 12(2):89-103. PubMed PMID: 22270953. 10.1038/nrc3205.
16. Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006, 66(1):283-289. CAN-05-2749. PubMed PMID: 16397241. 10.1158/0008-5472.
17. Frampton G.M., Ali S.M., Rosenzweig M., Chmielecki J., Lu X., Bauer T.M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015, CD-15-0285. PubMed PMID: 25971938. 10.1158/2159-8290.
18. Onozato R., Kosaka T., Kuwano H., Sekido Y., Yatabe Y., Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 2009, 4(1):5-11. PubMed PMID: 19096300. 10.1097/JTO.0b013e3181913e0e.
19. Network CGAR Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511(7511):543-550. PubMed PMID: 25079552; PubMed Central PMCID: PMCPMC4231481. 10.1038/nature13385.
20. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363(18):1693-1703. PubMed PMID: 20979469; PubMed Central PMCID: PMCPMC3014291. 10.1056/NEJMoa1006448.
21. Shaw A.T., Solomon B.J. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2015, 372(7):683-684. PubMed PMID: 25671264. 10.1056/NEJMc1415359.
22. Cui J.J., Tran-Dubé M., Shen H., Nambu M., Kung P.P., Pairish M., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 2011, 54(18):6342-6363. PubMed PMID: 21812414. 10.1021/jm2007613.
23. Oxnard S., Elkin E.K., Sullivan J.L., Carter D.A. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clin Lung Cancer 2015, PubMed PMID: 25769807. 10.1016/j.cllc.2015.01.009.
24. Paik P.K., Drilon A., Yu H., Rekhtman N., Ginsberg M.S., Borsu L., et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015, CD-14-1467. PubMed PMID: 25971939. 10.1158/2159-8290.
25. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., et al. RNA-guided human genome engineering via Cas9. Science. 2013, 339(6121):823-826. PubMed PMID: 23287722; PubMed Central PMCID: PMCPMC3712628. 10.1126/science.1232033.
26. Doudna J.A., Charpentier E. Genome editing, The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346(6213):1258096. PubMed PMID: 25430774. 10.1126/science.1258096.
27. Sander J.D., Joung J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 2014, 32(4):347-355. PubMed PMID: 24584096; PubMed Central PMCID: PMCPMC4022601. 10.1038/nbt.2842.
28. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339(6121):819-823. PubMed PMID: 23287718; PubMed Central PMCID: PMCPMC3795411. 10.1126/science.1231143.
29. Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337(6096):816-821. PubMed PMID: 22745249. 10.1126/science.1225829.
30. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2(5):401-404. CD-12-0095. PubMed PMID: 22588877; PubMed Central PMCID: PMCPMC3956037. 10.1158/2159-8290.
31. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6(269):pl1. PubMed PMID: 23550210; PubMed Central PMCID: PMCPMC4160307. 10.1126/scisignal.2004088.
32. Sogabe S., Togashi Y., Kato H., Kogita A., Mizukami T., Sakamoto Y., et al. MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations. Mol. Cancer Ther. 2014, 13(12):3098-3106. MCT-14-0429. PubMed PMID: 25253779. 10.1158/1535-7163.
33. Matsumoto K., Arao T., Hamaguchi T., Shimada Y., Kato K., Oda I., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br. J. Cancer 2012, 106(4):727-732. PubMed PMID: 22240789; PubMed Central PMCID: PMCPMC3322955. 10.1038/bjc.2011.603.
34. Togashi Y., Kogita A., Sakamoto H., Hayashi H., Terashima M., de Velasco M.A., et al. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett. 2015, 356(2 Pt. B):819-827. PubMed PMID: 25449777. 10.1016/j.canlet.2014.10.037.
35. Hubbard S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2004, 5(6):464-471. PubMed PMID: 15173825. 10.1038/nrm1399.
36. Asaoka Y., Tada M., Ikenoue T., Seto M., Imai M., Miyabayashi K., et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem. Biophys. Res. Commun. 2010, 394(4):1042-1046. PubMed PMID: 20331976. 10.1016/j.bbrc.2010.03.120.